Sionna Therapeutics (NASDAQ:SION) CFO Elena Ridloff Sells 748 Shares

Key Points

• Sionna Therapeutics CFO Elena Ridloff sold 748 shares at an average price of $25.18, decreasing her holdings to 47,368 shares valued at approximately $1.19 million.
• The company's stock price dropped 3.3% to $24.55, with a significant trading volume of 617,701 shares compared to an average of 193,090.
• Analysts have mixed views on the stock, with one upgrade to a "hold" rating and a target price of $36, while Raymond James set a "strong-buy" rating with a price target of $45.00.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) CFO Elena Ridloff sold 748 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $25.18, for a total value of $18,834.64. Following the completion of the transaction, the chief financial officer owned 47,368 shares in the company, valued at approximately $1,192,726.24. This represents a 1.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, September 2nd, Elena Ridloff sold 8,836 shares of Sionna Therapeutics stock. The stock was sold at an average price of $25.08, for a total value of $221,606.88.
• On Thursday, August 28th, Elena Ridloff sold 16,098 shares of Sionna Therapeutics stock. The stock was sold at an average price of $25.97, for a total value of $418,065.06.
• On Wednesday, August 27th, Elena Ridloff sold 3,618 shares of Sionna Therapeutics stock. The shares were sold at an average price of $25.10, for a total value of $90,811.80.
• On Tuesday, August 26th, Elena Ridloff sold 3,700 shares of Sionna Therapeutics stock. The shares were sold at an average price of $25.13, for a total value of $92,981.00.

Sionna Therapeutics Trading Down 9.9%

Shares of NASDAQ:SION traded down $2.38 during trading on Monday, hitting $21.62. 499,256 shares of the company's stock traded hands, compared to its average volume of 228,043. The company has a 50-day moving average price of $20.69 and a 200-day moving average price of $15.97. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $26.50.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.27.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth $109,258,000. TPG GP A LLC acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth $69,925,000. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth $38,639,000. Braidwell LP acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $18,770,000. Finally, Jennison Associates LLC acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth $8,995,000.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SION shares. Royal Bank Of Canada started coverage on Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price target on the stock. Wall Street Zen upgraded Sionna Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Raymond James Financial began coverage on Sionna Therapeutics in a research note on Tuesday, September 2nd. They set a "strong-buy" rating and a $45.00 target price for the company. Finally, Jones Trading began coverage on Sionna Therapeutics in a research note on Monday. They set a "buy" rating and a $46.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Sionna Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $38.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.